# A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

> **NCT00036543** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 1000 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Atrasentan

## Key facts

- **NCT ID:** NCT00036543
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1000 (—)
- **Last updated:** 2006-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036543, "A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00036543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*